The UMCC has a longstanding relationship with CALGB. UMCC staff participate in administrative, scientific, committee and planning activities within the CALGB. The UMCC faculty design, conduct and chair studies and enter patients onto multiple CALGB protocols. Funding to continue and expand these activities will allow for the evolution of UMCC in-house phase I(2-4/year) studies into group phase II studies. UMCC also conducts pilot studies which have formed the conceptual basis for groupwide studies. UMCC sees many new patients with acute leukemia and funding will enhance UMCC participation and entry of these patients onto CALGB studies. Specialized laboratories at UMCC including cytogenetics and pharmacology will serve as a resource for collaborative efforts and innovative data base for future CALGB studies. UMCC and its collaborating institutions (VA Hospital, Baltimore) and physicians, (Drs. Lichtenfeld, Lichtenfeld and Sachs) propose to enter 80 to 90 patients per year onto CALGB studies. Participation in CALGB studies will allow UMCC as well as collaborating physicians greater treatment options for patients with these diseases. UMCC has completed its in-house ANLL study seeking to verify data from another group member. Current participation includes the entry of patients with leukemia on to a pilot study of high dose maintainence. Ancillary activities are evaluating the cellular pharmacology and sensitivity of Ara-C as well as the cytogenetics of leukemia cells utilizing both standard and methotrexate sychronized high resolution banding techniques. Pilot studies in acute leukemia include clinical and pharmacokinetic phase II studies of investigational agents such as AZQ high dose Ara-C in combination with additional agents and in vitro differentiators. A UMCC study of 5-Azacytidine and etoposide led to a CALGB protocol for CML in blast crisis. All breast cancer patients seen at UMCC are entered onto CALGB studies and nearly 10% of stage IV study accrual has come from UMCC. The current stage IV study, and several phase II studies have been designed and chaired at UMCC. UMCC studies in small cell lung cancer have established an active three drug combination which will serve as the basis for a pilot study currently being proposed for group activation and is likely to serve as a portion of the new extensive disease protocol for this disease. UMCC will also participate in selected CALGB phase II studies in both small cell and non-small cell lung cancer. Patients with uncommon tumors such as soft tissue sarcomas will be entered onto the intergroup studies through CALGB. This grant will allow UMCC to enter patients onto CALGB studies, participate on CALGB committees, develop meritorious pilot protocols, monitor and collect data to produce mutual benefit to the UMCC and CALGB.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA031983-04
Application #
3557212
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1982-04-01
Project End
1988-03-31
Budget Start
1985-04-01
Budget End
1986-03-31
Support Year
4
Fiscal Year
1985
Total Cost
Indirect Cost
Name
University of Maryland Baltimore
Department
Type
Schools of Medicine
DUNS #
003255213
City
Baltimore
State
MD
Country
United States
Zip Code
21201
Beumer, Jan H; Owzar, Kouros; Lewis, Lionel D et al. (2014) Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Cancer Chemother Pharmacol 74:927-38
Rizzieri, David A; Johnson, Jeffrey L; Byrd, John C et al. (2014) Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002. Br J Haematol 165:102-11
Smith, Matthew R; Halabi, Susan; Ryan, Charles J et al. (2014) Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol 32:1143-50
Jeon, Justin; Sato, Kaori; Niedzwiecki, Donna et al. (2013) Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance. Clin Colorectal Cancer 12:233-8
Aggarwal, Rahul; Halabi, Susan; Kelly, William Kevin et al. (2013) The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) ( Cancer 119:3636-43
Lewis, Lionel D; Miller, Antonius A; Owzar, Kouros et al. (2013) The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance). Pharmacogenet Genomics 23:29-33
Jaklitsch, Michael T; Gu, Lin; Demmy, Todd et al. (2013) Prospective phase II trial of preresection thoracoscopic mediastinal restaging after neoadjuvant therapy for IIIA (N2) non-small cell lung cancer: results of CALGB Protocol 39803. J Thorac Cardiovasc Surg 146:9-16
Ogino, Shuji; Liao, Xiaoyun; Imamura, Yu et al. (2013) Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst 105:1789-98
Boylan, Alice M; Wang, Xiaofei F; Ko, Richard et al. (2013) Detection of human telomerase reverse transcriptase mRNA in cells obtained by lavage of the pleura is not associated with worse outcome in patients with stage I/II non-small cell lung cancer: results from Cancer and Leukemia Group B 159902. J Thorac Cardiovasc Surg 146:206-11
Edelman, Martin J; Shvartsbeyn, Marianna (2012) Epothilones in development for non--small-cell lung cancer: novel anti-tubulin agents with the potential to overcome taxane resistance. Clin Lung Cancer 13:171-80

Showing the most recent 10 out of 102 publications